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Abstract
Introduction: The aim of this study was to develop a clinical-grade, automated, multiplex system for the
differential diagnosis and molecular stratification of rheumatoid arthritis (RA).
Methods: We profiled autoantibodies, cytokines, and bone-turnover products in sera from 120 patients with a
diagnosis of RA of < 6 months’ duration, as well as in sera from 27 patients with ankylosing spondylitis, 28 patients
with psoriatic arthritis, and 25 healthy individuals. We used a commercial bead assay to measure cytokine levels
and developed an array assay based on novel multiplex technology (Immunological Multi-Parameter Chip
Technology) to evaluate autoantibody reactivities and bone-turnover markers. Data were analyzed by Significance
Analysis of Microarrays and hierarchical clustering software.
Results: We developed a highly reproducible, automated, multiplex biomarker assay that can reliably distinguish
between RA patients and healthy individuals or patients with other inflammatory arthritides. Identification of
distinct biomarker signatures enabled molecular stratification of early-stage RA into clinically relevant subtypes. In
this initial study, multiplex measurement of a subset of the differentiating biomarkers provided high sensitivity and
specificity in the diagnostic discrimination of RA: Use of 3 biomarkers yielded a sensitivity of 84.2% and a specificity
of 93.8%, and use of 4 biomarkers a sensitivity of 59.2% and a specificity of 96.3%.
Conclusions: The multiplex biomarker assay described herein has the potential to diagnose RA with greater
sensitivity and specificity than do current clinical tests. Its ability to stratify RA patients in an automated and
reproducible manner paves the way for the development of assays that can guide RA therapy.
Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory
condition characterized by polyarthritis of presumed
autoimmune etiology. Although the production of auto-
antibodies against synovial antigens and an increase in
cytokine levels are known to be associated with RA
[1,2], the molecular basis of the disease remains unclear.
Insight into the pathogenesis of RA – and hence effec-
tive treatment of RA – has been impeded by the hetero-
geneity of the disease. Not only can the disease course
range from mild and self-limiting to severe and progres-
sive, but also some patients respond well to early thera-
peutic intervention whereas others do not [3].
Therefore, there is a need for tests that can diagnose
early-stage RA, as well as tests that can predict which
RA patients will require and respond to anti-rheumatic
therapies.
Diagnostic tests currently used in the management of
early-stage RA are not sufficiently accurate, largely
because they are based on detection of single biomar-
kers that are either not specific to RA, e.g. rheumatoid
factor (RF) and C-reactive protein (CRP), or are present
in only a subset of RA patients, e.g. autoantibodies that
recognize cyclic citrullinated peptides (CCP). Even when
they correctly diagnose RA, current tests cannot ade-
quately predict the course of the disease or the response
to therapy because detection of a single biomarker can-
not differentiate between the multiple, distinct subtypes
of RA. Simultaneous analysis of multiple biomarkers
may be more informative, yielding ‘biomarker signatures’
of RA subtypes. Indeed, we previously demonstrated
that multiplex analysis of biomarkers in early-stage RA
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could define molecular subtypes of RA that correlated
with clinically identifiable RA subtypes [1,2]. Notably,
the presence of autoantibodies targeting citrullinated
proteins correlated with an increase in expression of
proinflammatory cytokines [2]. In addition, we recently
identified a biomarker signature of autoantibody specifi-
cities and cytokine levels that could distinguish between
RA patients who will respond to anti-TNF treatment
and those who will not [4].
Translation of these multiplex biomarkers onto a
highly reproducible, automated platform is necessary for
their use in robust validation studies and, ultimately,
clinical practice. In this study, we developed such a
highly reproducible, automated, multiplex biomarker
assay and tested its performance in the diagnosis of RA
and in the molecular stratification of RA patients into
clinically relevant subtypes.
Materials and methods
Roche multiplex automated assay
Roche Professional Diagnostics (Roche Diagnostics
GmbH, Penzberg, Germany) is developing a multiplex
platform called IMPACT (Immunological Multi-Para-
meter Chip Technology) that is based on a small poly-
styrene chip, as previously described [5]. During
manufacturing, the chip is coated with a streptavidin
layer onto which biotinylated markers – antibodies, pro-
teins, or peptides – are spotted in vertical rows for the
duplicate analysis of samples (Figure 1). Each chip con-
tains up to 10 different markers, and each marker is
arrayed on the chip as a vertical row of 10 to 12 spots; a
minimum of five spots is required for determination of
the level of a specific analyte in a sample. During the
assay, the arrayed markers are probed with a small
volume of sample and with a digoxigenylated secondary
monoclonal antibody. The secondary antibody is then
detected by the addition of an anti-digoxigenin antibody
conjugated to a fluorescent latex label. This label
enables sensitive detection of less than 10 individual
binding events in a single spot, down to fmol/L concen-
trations (Roche Diagnostics, Penzberg, Germany; pro-
prietary data on file). After this final incubation with
anti-digoxigenin antibody, chips are transferred to a
detection unit where a charge-coupled device camera
creates an image that is converted to signal intensities,
and fluorescence intensity of the array features is quan-
tified by image analysis. The IMPACT platform cur-
rently enables multiplex analysis of up to 10 analytes in
a sandwich or indirect antibody assay format, requires
only microliter quantities of serum samples, and is
highly sensitive. The throughput of the prototype is 40
determinations per hour. One run is intended to com-
prise 100 single determinations, including standards and
controls.
The chips and markers used in the present study are
listed in Table 1; the sequences of the peptides spotted
onto the chips are listed in Table S1 in Additional File
1. Autoantibody reactivities were measured in an indir-
ect immunoassay in which candidate RA antigens were
spotted onto the chips. Levels of analytes (e.g. inflamma-
tory and bone-turnover markers) were measured in a
sandwich immunoassay in which primary, capture anti-
bodies were spotted onto the chips. All antigens and
antibody pairs on these chronic inflammatory disease
(CID) chips were developed by Roche Diagnostics. For
measurement of RF, human anti-IgA and anti-IgM anti-
bodies were spotted onto the chip as capture antibodies,
and the RF they bound was then detected using biotiny-
lated polymerized human IgG. Antigens on the synovial
chips [see Table S1 in Additional File 1 were selected
through screens performed in the laboratory of Robin-
son et al. [1] or our collaborators’ laboratory [6]; they
were then synthesized and spotted onto IMPACT chips
by Roche Diagnostics. Using the appropriate chip-speci-
fic dilution buffers, we diluted the serum samples 1:10
for use in the synovial antigen 1 and 2, CID 3, and CID
4 chips, and 1:100 for use in the CID 1 chips. In the
assays using the synovial antigen 1 and 2, CID 1, CID 3,
or CID 4 chips, the arrayed antigens or antibodies were
probed with 40 μl of diluted serum sample, washed, and
then probed with 40 μl of digoxigenylated secondary
monoclonal antibody. In assays using the chips contain-
ing markers of bone turnover (bone chips), the arrayed
antibodies were probed with 40 μl of serum at a 1:2
dilution and then 20 μl of digoxigenylated monoclonal
antibody. Standards specific to each type of chip were
included in the assays using the CID 1, CID 3, CID 4,
and bone chips, and levels of each analyte were calcu-
lated on the basis of the standard curves generated.
Results for the synovial antigen 1 and 2 chips (for which
standards have not yet been generated) were reported
and analyzed as signal intensities. We minimized non-
specific binding by using fragments (Fab, Fab’, or Fab’2)
as capture antibodies and by using proprietary buffer
reagents (in addition to the standard casein, BSA, and
detergents) to minimize non-specific binding to the
solid phase. For the indirect immunoassays (CCP and
synovial chips), a proprietary detection antibody was
used that has been optimized to ensure minimal non-
specific binding. Extensive evaluation revealed that dilut-
ing the sample does not significantly influence non-spe-
cific binding (data not shown).
Multiplex cytokine assay
To measure cytokine or chemokine levels in sera, we
used the Milliplex Map Human cytokine/chemokine kit
(Millipore, Billerica, MA, USA) run on the Luminex 200
platform coupled with BioRad Bio-Plex software
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(BioRad, Hercules, CA, USA), according to the manufac-
turers’ protocols. The cytokines and chemokines mea-
sured were eotaxin, fibroblast growth factor 2,
granulocyte macrophage colony-stimulating factor, IL-
1a, IL-1b, IL-6, IL-12 (p40), IL-12 (p70), IL-15, IL-17,
IP-10, monocyte chemoattractant protein 1 (MCP-1),
and TNF. To prevent RF from bridging capture and
detection antibodies in the immunoassays, we added
Heteroblock (Omega Biologicals, Bozeman, MT, USA)
to the sera at a final concentration of 3 μg/ml (we have
shown that this concentration of Heteroblock eliminates
false augmentation of the readout by heterophilic anti-
bodies [2]). Calibration controls and recombinant stan-
dards were used as specified by the manufacturer.
Single automated assays
Roche Tina-Quant assays run on a fully automated plat-
form (Roche/Hitachi COBRAS C system) were used for
the individual, automated measurement of CRP and RF
levels in patient sera. In the CRP assay, latex particles
coated with monoclonal anti-CRP antibodies agglutinate
with human CRP. In the RF assay, latex-bound, heat-
inactivated IgG reacts with RF to form antigen-antibody
complexes. Both assays use turbidimetry to determine
latex agglutination, which occurs in cases of positive test
results.
Serum samples
All patient serum samples were used after obtaining
informed consent from the patients and under human
subjects protocols approved by the Stanford University
Institutional Review Board. Samples from RA patients
were obtained from ARAMIS (Arthritis, Rheumatism
and Aging Medical Information System), which includes
a biobank of serum samples from 793 Caucasian RA
patients who were recruited by a consortium of 161
practising rheumatologists throughout the USA [1,2,7,8].
All patients met the 1987 Arthritis College of
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Biglycan (247-266) 
Histone 2B/e (1-20) 
Fibromodulin (246-265) 
Fibromodulin (201-220) 
Vimentin (58-77) (Cit  64, 69, 71) 
Acetyl-calpastatin (184-210) 
Fibrinogen A (616-635) (Cit 621, 627, 630) 
Clusterin (170-188) 
Fibrinogen A (31-50) (Cit 35, 38, 42)    
Profilaggrin (293-310) (Cit 301, 302) 
Figure 1 Chips used for biomarker profiling on the IMPACT platform. (a) Images of an IMPACT synovial antigen chip 1 probed with sera
derived from a patient with RA. Fluoresence was captured with a charge-coupled device camera and quantified by software analysis. The
images are false color representations of the fluorescence signals detected. Blue represents low, green intermediate, yellow high, and white the
highest levels of fluorescence. The upper chip image is enhanced in the lower image by conversion of the lowest 5% of signals to black and the
top 5% of signals to white, with the color scale adjusted accordingly. The rheumatoid arthritis sample analyzed exhibits very high levels of
autoantibody reactivity to fibrinogen A (616-635) (Cit 621, 627, 630), vimentin (58-77) (Cit 64, 69, 71), and profilaggrin (293-310) (Cit 301, 302)),
and low levels of antibody reactivity to fibrinogen A (31-50) (Cit 35, 38, 42), biglycan (247-266), and histone 2B/e (1-20). (b) List of chips and their
components.
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Rheumatology criteria [9] and had RA of less than six
months’ duration. We used a randomisation algorithm
to select serum samples from 120 patients in the ARA-
MIS cohort. The baseline characteristics of this sub-
group of patients with early RA were assessed and
found to be comparable with those of the whole cohort
of patients [7]. Psoriatic arthritis (PsA) samples were
provided by James T. Elder and represent a mixture of
different subtypes of PsA (25% RA-like, 25% mutilans,
and 50% distal interphalangeal predominant disease).
Table 1 Chips and markers used on the IMPACT platform*
Chip name Chip components
Antigens Capture antibodies
Synovial antigen chip 1 Histone 2B/e (1-20)
Biglycan (247-266)
Fibromodulin (246-265)
Vimentin (58-77) (Cit 64, 69, 71)
Acetyl-calpastatin (184-210)
Fibromodulin (201-220)
Profilaggrin (293-310) (Cit 301, 302)
Clusterin (170-188)
Fibrinogen A (31-50) (Cit 35, 38, 42)
Fibrinogen A (616-635) (Cit 621, 627, 630)
Synovial antigen chip 2 Histone 2A (95-114)
Profilaggrin (293-310) (Cit 301, 305)
HSP60 (287-297)
Serine protease 11 (433-452)
Osteoglycin (177-196)
Apolipoprotein E (277-296) (Cit 278, 292)
Clusterin (334-353) (Cit 336, 339)
COMP (453-472)
CID 1 anti-CRP
anti-IgA (for RF measurement)
anti-IgM (for RF measurement)
CID 3 chip 1 Cit peptide 1
Cit peptide 2
Cit peptide 3
Cit peptide 4
CID 3 chip 2 Cit peptide 5
Cit peptide 6
Cit peptide 7
Cit peptide 8
Cit peptide 9
Cit peptide 10
Cit peptide 11
CID 4 anti-MMP 3
anti-IL-6
anti-S100 protein A8/A9
anti-E-Selectin
anti-HABP
Bone anti-PTH
anti-bCrosslaps
anti-Osteocalcin
anti-P1NP
*Candidate rheumatoid arthritis antigens were spotted on the chip for measurement of autoantibody reactivities. Primary antibodies were spotted on the chip
for measurement of analyte (e.g. inflammatory mediators and products of bone turnover) levels.
Cit, citrullinated; HSP 60, heat shock protein 60; COMP, cartilage oligomeric matrix protein; CRP, C-reactive protein; MMP3, matrix metalloproteinase 3; IL-6,
interleukin-6; HABP, hyaluronic acid binding protein; PTH, parathyroid hormone; P1NP, procollagen type 1 amino-terminal propeptide.
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Ankylosing spondylitis (AS) samples were provided by
John Reveille and represent a cohort of patients with
active axial and/or uveal disease. Serum samples from
healthy individuals were obtained from Bioreclamation,
Inc (Hicksville, NY, USA). All serum samples were
shipped on dry ice, stored at -80°C, and subjected to
one freeze-thaw cycle before being analyzed.
In assessing the analytical precision of the IMPACT
assay, we used serum samples from the REFLEX study,
a phase III trial on the efficacy of rituximab on a back-
ground of methotrexate in RA refractory to anti-TNF
therapy [10]. We used only samples obtained at baseline.
Statistical analysis
Values for each marker were divided by six times the
mean value obtained for that marker in the healthy control
samples and then log transformed. These normalized
values were analyzed by SAM (Significance Analysis of
Microarrays) [11,12]. Output was sorted based on false
discovery rates (FDRs) in order to identify antigens with
the greatest differences in autoantibody reactivity, or cyto-
kines with the greatest differences in concentrations,
between patients with RA, patients with other inflamma-
tory arthritides, and healthy individuals. Most of our com-
parisons involved high-dimensional data, and we therefore
used FDR for our exploratory analyses, an analytical
method that obviates the need for multiple corrections
when using high-dimensional data [11]. We then used
hierarchical clustering software (Cluster® 3.0, developed
by Michael Eisen at Stanford University, Stanford, Califor-
nia) to arrange the SAM results according to similarities
among patient samples in autoantibody specificities or
cytokine levels, and Java Treeview® (Java Treeview 1.1.3,
developed by Alok J. Saldanha at Stanford University,
Stanford, California) to graphically display the results.
To evaluate the IMPACT assay’s diagnostic sensitivity
and specificity, we used a subpanel of markers from the ori-
ginal array results – markers identified by univariate analy-
sis as ones that differentiate between patients with RA and
patients with other arthritides. A fluorescent value three
times the mean value of that obtained in healthy control
samples was defined as positive because this cutoff yielded
greater specificity than a cutoff of three standard deviations
above the mean. Similarly, because we had fewer healthy
controls than RA cases, this method provided greater speci-
ficity than did Z-normalization. We excluded RF values
from the analysis when comparing RF-positive and RF-
negative subgroups, and CCP values when comparing anti-
CCP-positive and anti-CCP-negative subgroups.
Results
Analytical precision of IMPACT assays
To develop a system for the multiplex analysis of differ-
ent types of biomarkers in the sera of RA patients, we
used a bead-based commercial assay (Millipore/Lumi-
nex) to evaluate cytokine levels, and an array-based
assay in development (IMPACT) to evaluate autoanti-
body reactivities and bone turnover. To determine the
intra-assay reproducibility achieved with the IMPACT
platform, we performed 21 replicate measurements of
each of nine markers within one run on the IMPACT
platform. The intra-assay coefficients of variance (CV)
ranged from 1.5 to 9.0% (Figure 2a). To determine
inter-assay reproducibility, we compared measurements
obtained from 5 to 15 independent runs of the same
sample at low, medium, and high dilutions; this was
done for eight of the markers present on the IMPACT
platform. Analysis demonstrated inter-assay CVs ranging
from 1.1 to 14.9% (Figure 2a). Notably, these results
compare favorably with CVs obtained with current com-
mercial ELISA tests for RF (which yield intra-assay CVs
of 6% and inter-assay CVs of 8%) [13] and CCP (which
yield intra-assay CVs of 4.8 to 13% and inter-assay CVs
of 9 to 17%) [14].
To assess the correlation between IMPACT multiplex
assays and single automated assays, we used both the
IMPACT and the Roche/Hitachi cobas c platforms to
measure RF and CRP in baseline serum samples from
subjects enrolled in the REFLEX study [10]. Linear
regression analysis demonstrated that the correlation
between the results from the multiplex assay and those
from the single assay was good, with correlation coeffi-
cients of 0.92 for RF and 0.97 for CRP (Figures 2b and
2c). Analysis of the bone-turnover markers with
IMPACT was previously described, the results of which
correlated well with those of corresponding single auto-
mated assays [5].
Biomarker signatures define distinct arthritides and
arthritis subtypes
To identify molecular signatures of arthritis subtypes, we
used antigen-containing chips on the IMPACT platform
to measure autoantibody reactivities and bone-turnover
markers [5], and bead-based assays on the Luminex
platform to measure cytokines, in serum samples from
120 patients with RA, 27 patients with AS, 28 patients
with PsA, and 25 healthy individuals. Values were nor-
malized as described in the methods, subjected to hier-
archical clustering, and displayed as a software-
generated heat map (Figure 3). As expected, autoanti-
body levels were significantly higher in RA patients than
in AS patients, PsA patients, or healthy controls. How-
ever, within the pool of RA patients were subgroups
with distinct patterns of autoantibody specificities,
including a subgroup with minimal autoantibody reac-
tivity. Elevations in cytokine levels clearly distinguished
certain subsets of patients with RA, AS, or PsA from
healthy individuals. Certain subsets of arthritis patients
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had lower cytokine levels than did other patients with
the same diagnosis. As autoantibody production is not
typically a feature of PsA, the detection of autoantibo-
dies in several patients diagnosed with PsA (Figure 3)
raises the possibility that evaluation of a larger panel of
autoantibodies than that measured by the commercially
available assays may be able to correct misdiagnosis.
In contrast to previous findings [15,16] we did not
find an association between RA and markers of bone
turnover. This is perhaps not surprising given that our
analysis was done using a cohort of patients with early-
stage RA, and erosion of bone occurs in established and
advanced RA. In contrast, an association between AS
and elevated levels of markers of bone turnover – speci-
fically, beta crosslaps, and osteocalcin – was revealed in
the course of the biomarker analysis (Figure 4),
suggesting that activation of bone-turnover pathways,
exceeding that seen in RA or PsA, occurs in AS. Also
intriguing was the increase in levels of the bone-marker
parathyroid hormone. However, because levels of para-
thyroid hormone are heavily influenced by vitamin D
status [17] (a variable not accounted for in our study),
firm conclusions about associations between parathyroid
hormone and AS cannot be drawn from our present
data. Levels of proinflammatory cytokines were also sig-
nificantly higher in AS patients than in healthy indivi-
duals, in line with previous findings [18,19].
Association of biomarker signatures with parameters
predictive of severe RA
Using research-grade platforms, we previously demon-
strated an association between specific biomarker
Intraassay CV% Interassay CV%
CID1 Rf-IgM 2.5-4.3 1.1-4.0
Rf-IgA 4.7-7.7 1.9-6.3
CRP 5.2-5.4 5.3-12.6
SAA 4.6-8.7 2.7-4.8
CID4 MMP3 3.9-4.6 8.6-14.6
IL6 2.9-6.5 11.6-12.0
E-Selecn 3.9-9.0 7.2-8.8
S100A8/A9 1.5-5.5 5.0-14.9
Hyaluronic Acid 2.3-4.6 n.t.
Figure 2 Analytical precision of selected IMPACT assays and comparison with standard single assays. (a) Analytical precision. Intra-assay
coefficients of variance (CV) were generated by performing 21 replicate measurements of each of nine markers in one sample within one run
on the IMPACT platform. Inter-assay CVs were calculated based on results from 5 to 15 independent runs of the same sample on the IMPACT
platform. The range of the CV for each marker corresponds to that of three independent pools of sample analyzed at low, medium, and high
concentrations. (b) Correlation of values obtained with the Roche IMPACT platform with those obtained with the standard Roche Tina Quant
(latex aggregation) assay. IgM autoantibody reactivity to rheumatoid factor (IgM-RF) in 1,312 RA serum samples was measured with the IMPACT
platform and with Tina Quant assay. C-reactive protein (CRP) levels in 1,198 RA serum samples were measured with the IMPACT platform and
with Tina Quant assay. Linear regression was used to determine the correlation between the multiplex chip assay (IMPACT) and the standard
single assay (Tina Quant). IL-6, interleukin-6; MMP3, matrix metalloproteinase 3; SAA, serum amyloid A.
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Figure 3 Proteomic characterization of serum samples from patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing
spondylitits. Autoantibody reactivities and levels of bone-turnover products in serum samples from 120 patients with rheumatoid arthritis (RA),
27 patients with ankylosing spondylitits (AS), 28 patients with psoriatic arthritis (PSA), and 25 healthy individuals were measured on the IMPACT
platform. Cytokine levels were measured with a bead-based assay (Millipore) run on the Luminex platform. Values were normalized as described
in the methods and subjected to hierarchical clustering; individual patients are listed above the heat map and the individual cytokines and
antigens are listed to the right of the heat map. Cytokine levels and autoantibody reactivities are displayed, with blue representing a decrease
relative to the mean value obtained in samples from healthy individuals, yellow no change, and red an increase. Cit, citrullinated; COMP,
cartilage oligomeric matrix protein; CRP, C-reactive protein; FGF-2, fibroblast growth factor 2; GM-CSF, granulocyte macrophage colony-
stimulating factor; HABP, hyaluronic acid binding protein; HSP 60, heat shock protein 60; IL, interleukin; MCP-1, monocyte chemoattractant
protein 1; MMP3, matrix metalloproteinase 3; P1NP, procollagen type 1 amino-terminal propeptide; PTH, parathyroid hormone; RF, rheumatoid
factor; TNFa, tumor necrosis factor a.
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signatures and the presence of RF, anti-CCP antibodies,
or shared-epitope (SE) alleles [1,2], each of which pre-
dicts progression to severe RA [20]. To determine
whether the automated IMPACT platform could recapi-
tulate this finding, we used the IMPACT platform in
conjunction with bead-based multiplex assays to charac-
terize serum samples from 120 RA patients, of which 73
had anti-CCP antibodies (as assessed by the IMPACT
assay), 78 had RF (as assessed by the IMPACT assay),
and 74 had one or two SE alleles. We performed our
analysis using a subset of the antigen markers we used
previously [1,2,4], as well as an additional set of analyte
assays previously developed for use on the IMPACT
platform (Figure 1). Data from the CCP-containing
chips used to determine anti-CCP-antibody status of the
patient samples (i.e., CID 3 chips 1 and 2) were
excluded from analyses comparing patients on the basis
of presence or absence of anti-CCP antibodies.
We again demonstrate a clear association between the
presence of anti-CCP (Figure 5) or RF (Figure 6) antibo-
dies and increased targeting of RA-associated autoanti-
gens – most citrullinated, but some native. Notably,
distinct but overlapping sets of antigens were targeted
in RF-positive patients compared with anti-CCP-anti-
body-positive patients. Likewise, the pattern of increases
in cytokine levels showed both differences and similari-
ties between RF-positive patients and anti-CCP-anti-
body-positive patients. Despite the strong association
between seropositivity (the presence of RF and/or anti-
CCP antibodies) and elevation of serum cytokines, a
subset of seronegative patients had significantly elevated
serum cytokines, possibly reflecting a subpopulation
more clinically and immunologically similar to those
who can be defined as seropositive. When we sought to
identify differences on the basis of the presence or
absence of SE alleles, we found that the presence of SE
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Figure 4 Increased markers of bone metabolism in ankylosing spondylitis. Autoantibody reactivity and bone-turnover products were
characterized on the IMPACT platform in 27 ankylosing spondylitis (AS) patients and 25 healthy individuals. Cytokine levels in the same samples
were measured using a bead-based assay run on the Luminex platform. Values were normalized as described in the methods. Significance
Analysis of Microarrays (SAM) followed by a hierarchical clustering algorithm were used for determination of cluster relations that group patient
samples (top dendrogram) and antigen reactivities (right dendrogram) based on similarities in patient autoantibodies and cytokines (false
discovery rate < 1). Dendrogram branch lengths and distances between nodes illustrate the extent of similarities in antigen reactivity and
cytokine levels, with blue representing a decrease relative to the mean value obtained in samples from healthy individuals, yellow no change,
and red an increase. Bone-turnover markers are in red text. GM-CSF, granulocyte macrophage colony-stimulating factor; IL, interleukin; PTH,
parathyroid hormone; TNFa, tumor necrosis factor a.
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alleles was associated with increased targeting of RA-
associated autoantigens; however, unlike the presence of
RF or anti-CCP antibodies, the presence of SE alleles
alone was not associated with elevations in serum cyto-
kines (Figure 7). There was no significant difference
between carrying one versus two copies of the SE allele
(data not shown).
Autoantibody and cytokine signatures as sensitive and
specific diagnostics of RA
Using univariate analysis, we determined which of the
biomarkers (out of 31 autoantigens, 4 bone markers, 5
inflammatory mediators, and 14 cytokines) distinguish
RA patients from a pool of 120 patients with early-stage
RA, 27 patients with AS, 28 patients with PSA, and 25
healthy individuals. We found that a panel of six auto-
antigens distinguished RA. We then used the same
serum samples to evaluate the diagnostic sensitivity and
specificity of different combinations of the individual
autoantigens in this differentiating panel of six biomar-
kers. The sensitivity and specificity of these subpanels in
the differential diagnosis of RA were similar to that of
anti-CCP status [21] and better than that of RF status
[22] (Table 2).
Discussion
We report the development of a highly reproducible,
automated, multiplex biomarker assay that can reliably
distinguish RA patients from healthy individuals or
patients with other inflammatory arthritides. Multiplex
measurement of a subset of the differentiating biomar-
kers provided high sensitivity and specificity in the diag-
nostic discrimination of RA. Furthermore, the
biomarker profiles we identified enabled stratification of
RA patients into distinct, clinically relevant subtypes.
Current clinical tests fall short of being accurate and
all-encompassing diagnostics of RA because RF is not
specific to RA and anti-CCP antibodies are not pro-
duced in all cases of RA. Compared with single-biomar-
ker detection, multiplex-biomarker detection – by
casting the net wider – provides greater sensitivity and
specificity of diagnosis. Although they remain to be
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Figure 5 Autoantibodies and cytokine levels stratified according to anti-CCP seropositivity. Autoantibody and cytokine levels are higher
in anti- cyclic citrullinated peptide (CCP)-antibody-positive than in anti-CCP-antibody-negative RA. Serum samples from 73 patients with anti-
CCP-antibody-positive RA and from 47 patients with anti-CCP-antibody-negative RA were analyzed. Chips containing CCP were excluded from
this analysis. Autoantibody reactivity was assessed on the IMPACT platform and cytokine levels were measured in a bead-based assay run on the
Luminex platform. For assays run on the IMPACT platform, values were normalized as described in the methods. Significance Analysis of
Microarrays (SAM) followed by a hierarchical clustering algorithm were used to determine cluster relations that group patient samples (top
dendrogram) and antigen reactivities (right dendrogram) on the basis of similarities in patient autoantibody and cytokine profiles (false discovery
rate < 1). Dendrogram branch lengths and distances between nodes illustrate the extent of similarities in antigen reactivity and cytokine levels,
with blue representing a decrease relative to the mean value obtained in samples from healthy individuals, yellow no change, and red an
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stimulating factor; IL, interleukin; RF, rheumatoid factor; TNFa, tumor necrosis factor a.
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Figure 6 Autoantibodies and cytokine levels stratified according to RF seropositivity. Autoantibody and cytokine levels are higher in
rheumatoid factor (RF)-positive RA than in RF-negative RA. Serum samples from 78 patients with RF-positive RA and from 42 patients with RF-
negative RA were analyzed. Autoantibody reactivity was assessed on the IMPACT platform and cytokine levels were measured in a bead-based
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validated in independent cohorts of RA patients, our
preliminary results suggest that our biomarker assay has
the potential to provide greater diagnostic sensitivity
and specificity than that provided by current clinical
tests. Including in our analysis a larger number of con-
trol patients with non-RA inflammatory diseases should
allow us to further increase the sensitivity and specificity
of our biomarker assay. Whereas the commercial anti-
CCP-antibody assay relies on the measurement of anti-
body reactivity against a mixture of different citrulli-
nated peptides, our multiplex biomarker assay allows
measurement of antibody reactivity against each of sev-
eral different citrullinated peptides independently, thus
enabling more-precise diagnostic characterization.
Moreover, the integrated evaluation of multiple addi-
tional biomarkers (i.e. autoantibody specificities, cyto-
kine levels, and bone-turnover products) enables the
stratification of RA into disease subtypes and provides
further insight into disease pathogenesis at the indivi-
dual level. For instance, our biomarker assay identified a
subset of seronegative RA patients who had elevations
in serum cytokines suggestive of more aggressive dis-
ease, an association that would have gone undetected
with current clinical tests.
As RA is such a heterogeneous disease, diagnosis must
be accompanied by prognosis in order to identify which
patients with early-stage RA are in need of aggressive
therapeutic intervention. The presence of serum RF or
anti-CCP antibodies is associated with progression to
severe RA [23-25]. When combined, these two biomar-
kers offer a somewhat improved prognostic capability
[26]. Although we did not observe an association of
bone-turnover markers with early-stage RA in this
study, elevations in markers of bone and cartilage
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turnover [27] also have been proposed to predict a more
destructive course of RA, as have elevations in acute-
phase reactants [28]. Multiplex biomarker detection
should be more accurate and informative than single-
biomarker detection in RA prognosis, as it is in diagno-
sis. We show here that multiplex biomarker detection in
early-stage RA can identify biomarker signatures that
are associated with immunological (presence of anti-
CCP-antibodies or RF) and genetic (possession of SE
alleles) parameters predictive of more severe RA. Unfor-
tunately, information on the degree of radiographic joint
damage at the time of diagnosis, a powerful predictor of
disease outcome, was not available for the cohort we
analyzed. In addition, the greater use of disease-modify-
ing anti-rheumatic drugs in patients with RF-positive
RA confounded attempts to correlate our biomarker sig-
natures with disability at diagnosis (as assessed by the
Stanford Health Assessment Questionaire), a good pre-
dictor of later functional impairment [29]. In addition to
validating out present findings in an independent cohort
of patients, we aim to evaluate the prognostic utility of
our assay. Given that our biomarker panel enables dis-
ease stratification and yields detailed molecular informa-
tion, we expect that it will provide more precise
prognosis than that achieved in the clinic at present.
Although not an overt objective of the present study,
our biomarker analysis revealed that AS is associated with
elevated levels of bone-turnover markers and cytokines, in
line with previous findings [18,30]. The small number of
AS patients included in this study precludes any firm con-
clusions, but this observation suggests that our multiplex
platform may be useful in developing a diagnostic or prog-
nostic test for AS – a major unmet clinical need.
This exploratory study has several limitations. Given
that we were unable to adjust for treatment-related
effects on the studied biomarkers, it is possible that use
of immunosuppressant therapy could affect levels of
serum cytokines and thereby confound interpretation of
our data. In addition, the ARAMIS RA cohort studied
represents a Caucasian, American, early-RA cohort, and
therefore it is possible that our findings cannot be extra-
polated to all RA patients; our findings remain to be
validated in independent and more diverse cohorts. In
addition, the fact that RA and control patients were not
matched by demographics or by handling of their serum
samples could bias our results.
Conclusions
In the diagnosis and prognosis of RA, measurement of a
single biomarker is not sufficiently sensitive or accurate,
and individual measurement of multiple biomarkers is
labor intensive and therefore expensive. Automated multi-
plex biomarker analyses can help to reduce the laboratory
workload involved in the analysis of multiple biomarkers
and can provide greater sensitivity and specificity. How-
ever, their use in clinical trials has been hampered by their
limited reproducibility between and within multiplex plat-
forms. The multiplex system we developed in this study is
ideally suited to the simultaneous analysis of multiple bio-
markers because it uses a standardized assay platform and
is highly automated, allowing high-throughput reproduci-
bility across clinical laboratories. Here we demonstrate the
effectiveness of this multiplex biomarker assay in stratify-
ing RA into clinically relevant subtypes. The ability to clas-
sify RA patients in an automated and reproducible manner
paves the way for further studies aimed at attaining perso-
nalized medicine for RA.
Additional material
Additional file 1: Sequences of peptides spotted on synovial
antigen chip 1 and 2. Supplementary table showing the amino acid
sequences of the peptides spotted onto synovial antigen chips 1 and 2.
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